With this in mind, the development of an improved understanding of the fundamental mechanisms of trastuzumab action and molecular determinants of response, and the identification of therapeutic agents that can either potentiate the effect of trastuzumab or target cells which have become resistant to trastuzumab have become a major focus for the treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.